# Filing Detail

Form 8-K - Current report:
SEC Accession No. 0001628280-22-001252
Filing Date
2022-01-25
Accepted
2022-01-25 17:13:52
Documents
14
Period of Report
2022-01-25
Items
Item 2.02: Results of Operations and Financial Condition
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | 8-K | xfor-20220125.htm iXBRL | 8-K | 43041
2 | EX-99.1 | ex991jan252022.htm | EX-99.1 | 1101
6 |  | image_0a.jpg | GRAPHIC | 585688
| Complete submission text file | 0001628280-22-001252.txt |  | 997675

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
3 | XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT | xfor-20220125.xsd | EX-101.SCH | 1914
4 | XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT | xfor-20220125_lab.xml | EX-101.LAB | 25998
5 | XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT | xfor-20220125_pre.xml | EX-101.PRE | 13731
8 | EXTRACTED XBRL INSTANCE DOCUMENT | xfor-20220125_htm.xml | XML | 11887

Mailing Address 61 NORTH BEACON STREET 4TH FLOOR BOSTON MA 02134
Business Address 61 NORTH BEACON STREET 4TH FLOOR BOSTON MA 02134 857-529-8300
X4 Pharmaceuticals, Inc (Filer) CIK: 0001501697 (see all company filings)

EIN.: 273181608 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38295 | Film No.: 22554734
SIC: 2836 Biological Products, (No Diagnostic Substances)